Recombinant Anti-CD28 x Anti-CD3 Bispecific Antibody (VHH-IgG) (BSSG-366)

Recombinant Anti-CD28 x Anti-CD3 Bispecific Antibody (VHH-IgG) is formed by an IgG and two VHH fragments. The VHHs from an anti-CD3 antibody variable domain are respectively connected to the N terminus of the anti-CD28 IgG heavy chains or light chains to form VHH-(H)IgG or VHH-(L)IgG. It is a type of appended IgGs and has 2+2 antigen-binding valency. This BsAb can improve T-cell activation. It is designed for the research of Tumors therapy.

Datasheet INQUIRY

Specifications

Targets

CD28 & CD3

Type

Appended IgGs

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Tumors

Targets

Target 1

CD28

Gene ID

940

UniProt ID

P10747

Alternative Names

CD28; CD28 molecule; Cluster of Differentiation 28; Tp44; T-cell-specific surface glycoprotein CD28; CD28 antigen

Target 2

CD3

Gene ID

916

UniProt ID

P07766

Alternative Names

CD3; CD3E; CD3e molecule; Cluster of differentiation 3; CD3e molecule, epsilon (CD3-TCR complex); T3E; TCRE; IMD18; T-cell surface glycoprotein CD3 epsilon chain; CD3-epsilon; T-cell surface antigen T3/Leu-4 epsilon chain; CD3e antigen, epsilon polypeptide (TiT3 complex); T-cell antigen receptor complex, epsilon subunit of T3

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-CD28 x Anti-CD3 Bispecific Antibody (VHH-IgG) (BSSG-366). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-CD28 x Anti-CD3 Bispecific Antibody (VHH-IgG) (CAT#: BSSG-366)

Specifications

Targets

Customer Reviews and Q&As